Tankyrase 2 as a therapeutic target in non-small cell lung cancer: Implications for apoptosis and migration

doi:10.5306/wjco.v16.i3.103234

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (71)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=61

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=6

Mar 24, 2025 (publication date) through Jan 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Clin Oncol. Mar 24, 2025; 16(3): 103234
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.103234

Tankyrase 2 as a therapeutic target in non-small cell lung cancer: Implications for apoptosis and migration

Jing Yu, Bo-Tao Xu, Qiu Li, Zhong-Tu Shang

Jing Yu, Qiu Li, Zhong-Tu Shang, Department of Respiratory Medicine, Zhuji people’s Hospital, Zhuji 311800, Zhejiang Province, China

Bo-Tao Xu, Department of Cardiothoracic Surgery, Zhuji People’s Hospital, Zhuji 311800, Zhejiang Province, China

Author contributions: Yu J and Li Q conceptualization and writing of the original draft; Shang ZT formal analysis and validation; Xu BT conceptualization, writing, reviewing and editing. All authors participated in drafting the manuscript and all have read, contributed to, and approved the final version of the manuscript.

Conflict-of-interest statement: No author has stated that there are any commercial, professional, or personal conflicts of interest relevant to the study, proving that it complies with the principles of publishing ethics.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Bo-Tao Xu, MD, Assistant Professor, Postdoctoral Fellow, Department of Cardiothoracic Surgery, Zhuji People’s Hospital, No. 9 Jianmin Road, Taozhu Street, Zhuji 311800, Zhejiang Province, China. 18888755957@163.com

Received: November 13, 2024
Revised: December 14, 2024
Accepted: December 20, 2024
Published online: March 24, 2025
Processing time: 70 Days and 1.9 Hours

Core Tip

Core Tip: Tankyrase 2 (TNKS2) drives the progression of non-small cell lung cancer (NSCLC) by inhibiting apoptosis and promoting cell migration, significantly activating the β-catenin pathway. This function underscores TNKS2's potential as a therapeutic target in NSCLC; however, additional in vivo studies are needed to confirm its role and to evaluate its expression in clinical samples for prognostic use. Combining TNKS2 inhibitors with apoptosis-inducing drugs may enhance therapeutic efficacy, while targeted delivery methods could reduce off-target effects in healthy tissues, advancing the development of TNKS2-focused treatment strategies in NSCLC management.